The SELUTION SLR sirolimus-eluting balloon maintained an 81.5% primary patency rate with minimal late catch-up phenomenon through 3 years in patients with symptomatic femoropopliteal disease, marking the first published long-term data for a sirolimus drug-eluting balloon (DEB) in peripheral arterial intervention.